Last updated on January 2020

A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF


Brief description of study

Idiopathic pulmonary fibrosis (IPF) is a rare, progressive life-threatening disease that is characterized by exertional dyspnea and persistent dry cough.

Cough in IPF is both a presenting and a complicating clinical feature, which affects approximately three quarters of IPF cases. It is often a debilitating symptom that adversely affects quality of life (QoL) and is usually refractory to medical therapy.

Inhaled RVT-1601 (formerly, PA101B), a new inhalation formulation of cromolyn sodium delivered via the eFlow Closed System (CS) nebulizer, is being evaluated in this Phase 2b study for the treatment of persistent cough in patients with IPF.

Clinical Study Identifier: NCT03864328

Find a site near you

Start Over

Mater Research

South Brisbane, Australia
2.02miles
  Connect »

Lung Research Quensland

Chermside, Australia
4.31miles
  Connect »